QCM
FDMT icon

Quantinno Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Quantinno Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$772K Buy
58,082
+14,557
+33% +$142K ﹤0.01% 2746
2026
Q1 		$405K Sell
43,525
-2,775
-6% -$24.1K ﹤0.01% 2853
2025
Q4 		$347K Buy
46,300
+10,853
+31% +$110K ﹤0.01% 2731
2025
Q3 		$308K Buy
+35,447
New +$212K ﹤0.01% 2432

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Quantinno Capital Management's FDMT Position: Q2 2026 in Review

Quantinno Capital Management increased its 4D Molecular Therapeutics (FDMT) stake by 33% in Q2 2026, buying an estimated $142K and bringing the position to 58,082 shares worth $772K. The position accounts for ﹤0.01% of the portfolio, ranked #2746.

Quantinno Capital Management first reported a position in FDMT in Q3 2025 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Quantinno Capital Management held 58,082 shares of 4D Molecular Therapeutics worth $772K as of Q2 2026.
  • Quantinno Capital Management bought 14,557 4D Molecular Therapeutics shares in Q2 2026, an estimated $142K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2746 holding.
  • Quantinno Capital Management first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.